ADAPT for COVID Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in senate (Oct 7, 2021)
Accelerated Drug Approval for Prescription Therapies for Coronavirus Act or the ADAPT for COVID Act
This bill authorizes the Food and Drug Administration (FDA)to create an expedited drug approval process specifically for drugs that are currently approved for sale in certain countries (i.e., a European Economic Area member country, Australia, Canada, Israel, Japan, New Zealand, South Africa, or Switzerland) and meet certain criteria. Such criteria shall include establishing that (1) the drug is safe and effective, (2) all relevant U.S. patents or legal exclusivities have expired, and (3) the drug is intended to treat or prevent COVID-19 or another disease of epidemic potential.
The FDA must process and review an application under this bill within 180 days of submission.
What just happenedOct 7, 2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Who’s behind it
- Introduced in SenateOct 7, 2021
- Oct 7, 2021IntroReferral
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health, Education, Labor, and Pensions Committee - Oct 7, 2021IntroReferral10000
Introduced in Senate